CFM
IBRX icon

Catalyst Funds Management’s ImmunityBio IBRX Stock Holding History

Catalyst Funds Management’s Portfolio IBRX Stock Details IBRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-20,600
Closed -$76.6K – 772
2024
Q3 		$76.6K Sell
20,600
-1,000
-5% -$4.63K 0.02% 596
2024
Q2 		$137K Buy
+21,600
New +$142K 0.04% 243

Other funds holding IBRX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Catalyst Funds Management's IBRX Position: Q4 2024 in Review

Catalyst Funds Management sold out of ImmunityBio (IBRX) in Q4 2024, closing a stake of 20,600 shares — an estimated $76.6K sold.

Catalyst Funds Management first reported a position in IBRX in Q2 2024 and held it in 2 quarters. The position peaked at $137K in Q2 2024. 201 funds tracked by Wall St. Rank hold IBRX as of Q4 2024.

  • Catalyst Funds Management reported no remaining ImmunityBio position as of Q4 2024 after selling out during the quarter.
  • Catalyst Funds Management sold 20,600 ImmunityBio shares in Q4 2024, an estimated $76.6K.
  • Catalyst Funds Management first reported a position in ImmunityBio in Q2 2024 and held it in 2 quarters.
  • Catalyst Funds Management's ImmunityBio position peaked at $137K in Q2 2024.
  • 201 funds tracked by Wall St. Rank held ImmunityBio as of Q4 2024.

Based on Catalyst Funds Management's 13F filing for Q4 2024, filed 10 Feb 2025.